Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adentri
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Adentri is an oral small molecule drug that functions as an adenosine receptor antagonist. It was developed by Biogen (formerly Biogen Idec) and investigated for the treatment of heart failure. Its mechanism of action is designed to maintain renal function and promote natriuresis (sodium excretion) in patients with heart failure. The drug progressed to Phase II clinical trials for stable heart failure and subsequently to Phase III for acute decompensated heart failure patients with renal insufficiency. Its development involved a licensing agreement with CV Therapeutics.
- Brand names
- Adentri
02
Targets
ADOR (Adenosine receptors)
Beyond the preview
Go deeper on Adentri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adentri.